lilly's natural foods LLC

988 halsey st. apt. 3
brooklyn, new york 11207

NYS Entity Status
ACTIVE

NYS Filing Date
JULY 18, 2014

NYS DOS ID#
4608528

County
ALBANY

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC LIMITED LIABILITY COMPANY

Name History
2014 - LILLY'S NATURAL FOODS LLC









Buffer

submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • Blink Health Ends Pact With Express Scripts for Lilly Insulin Price Discounts
    Tuesday Jun 13, 2017

    Blink Health LLC, a provider of consumer price discounts for prescription drugs, said it has terminated its relationship with Express Scripts Holding Co., a pharmacy-benefit manager that helped arrange the new price break for Lilly’s insulin.

    Source: The Wall Street Journal: U.S. Business
  • Neighborhood Joint: Staubitz Market in Brooklyn: 100 Years of Sawdust, Steaks and Chops
    By ANDREW COTTO - Wednesday Jun 14, 2017

    A display contains frozen items, and the shelves are stocked with jars and cans. But there’s just one reason to visit this Boerum Hill business: meat.

    Source: NYT > Home Page
  • Can Gowanus Survive Its Renaissance?
    By ANDY NEWMAN - Friday Oct 13, 2017

    Brooklyn’s famously filthy canal is getting cleaned up. New construction is coming to the area. And not everyone is happy.

    Source: NYT > Home Page
  • Rooted in Counterculture, Whole Foods’ Founder Finds an Unlikely Refuge
    By MICHAEL J. de la MERCED and ALEXANDRA STEVENSON - Friday Jun 16, 2017

    John Mackey wanted to fight off the activist investors attacking Whole Foods. He found a savior in Amazon, a company blamed for laying waste to retailers.

    Source: NYT > Home Page
  • Shareholders Demand More Drastic Shifts at Nestlé
    By STEPHANIE STROM - Tuesday Jun 27, 2017

    The changes requested by the Third Point hedge fund underscore the idea that legacy food brands must radically shake up their portfolios to remain profitable.

    Source: NYT > Home Page
  • Eli Lilly Fronts $55M for Rights to KeyBioscience’s Diabetes Drugs
    By Frank Vinluan - Thursday Jun 8, 2017

    With competition threatening to chip away at its diabetes stronghold, Eli Lilly is shoring up its pipeline with a deal that gives the company access to a potential new class of diabetes drugs. Indianapolis-based Lilly (NYSE: LLY) has agreed to pay $55 million up front to KeyBioscience in exchange for rights to compounds in various […]

    Source: Xconomy VC, Deals, & Startups Feed